Takahiko Shibahara1, Takamichi Morikawa2, Kaori Yago3, Hiromitsu Kishimoto4, Yutaka Imai5, Kenichi Kurita6. 1. Professor and Chairman, Department of Oral and Maxillofacial Surgery, Tokyo Dental College, Tokyo, Japan. Electronic address: sibahara@tdc.ac.jp. 2. Assistant Professor and Chairman, Department of Oral and Maxillofacial Surgery, Tokyo Dental College, Tokyo, Japan. 3. Director, Department of Oral and Maxillofacial Surgery, Mita Hospital, International Health and Welfare University, Tokyo, Japan. 4. Professor and Chairman, Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, Hyogo, Japan. 5. President, Japanese Society of Dentistry for Medically Compromised Patient and Dokkyo University, Tochigi, Japan. 6. President, Japanese Society of Oral and Maxillofacial Surgeons and School of Dentistry, Aichi-Gakuin University, Aichi, Japan.
Abstract
PURPOSE: From 2011 to 2013, a nationwide retrospective cohort study was conducted by the Japanese Society of Oral and Maxillofacial Surgeons and the Japanese Society of Dentistry for Medically Compromised Patients to assess the development of bisphosphonate (BP)-related osteonecrosis of the jaws (BRONJ) and to elucidate the outcomes and factors associated with remission. MATERIALS AND METHODS: A written questionnaire, including clinical characteristics, management, and outcomes of patients with BRONJ, was sent to 501 institutions. RESULTS: This large-scale study included 4,797 cases with a female preponderance. BRONJ occurred twice as often in the mandible as in the maxilla. Most patients had BRONJ stage 2 (61.4%), followed by stage 1 (20.7%) and stage 3 (16.8%); stage 0 was excluded. The most common primary disease was malignant neoplasm (46.5%), followed by osteoporosis (including prevention; 45.3%). The proportion of patients on oral BPs increased, with the incidence approaching that of patients receiving parenteral BP. Surgical therapy rates of patients with BRONJ stages 1, 2, and 3 were 14.0, 37.6, and 53.5%, respectively. Outcome assessment for 936 patients with BRONJ stage 2 who underwent surgical therapy indicated remission in 46.3% of cases, improvement in 30.6%, disease progression in 5.4%, and no change in 6.1%. Good prognosis (remission or improvement) was seen in 76.9% of cases and poor prognosis (disease progression or no change) was seen in 11.5%. Analysis showed that risk factors for onset of BRONJ (P = .031), surgical procedure (P < .024), condition of the wound (P = .017), and discontinuation of BP (P < .001) were factors affecting prognosis. CONCLUSION: The number of patients with BRONJ has increased in Japan. Attention to oral BP and proper treatment is required to minimize the number of cases. Surgical therapy seems to be effective for BRONJ stage 2.
PURPOSE: From 2011 to 2013, a nationwide retrospective cohort study was conducted by the Japanese Society of Oral and Maxillofacial Surgeons and the Japanese Society of Dentistry for Medically Compromised Patients to assess the development of bisphosphonate (BP)-related osteonecrosis of the jaws (BRONJ) and to elucidate the outcomes and factors associated with remission. MATERIALS AND METHODS: A written questionnaire, including clinical characteristics, management, and outcomes of patients with BRONJ, was sent to 501 institutions. RESULTS: This large-scale study included 4,797 cases with a female preponderance. BRONJ occurred twice as often in the mandible as in the maxilla. Most patients had BRONJ stage 2 (61.4%), followed by stage 1 (20.7%) and stage 3 (16.8%); stage 0 was excluded. The most common primary disease was malignant neoplasm (46.5%), followed by osteoporosis (including prevention; 45.3%). The proportion of patients on oral BPs increased, with the incidence approaching that of patients receiving parenteral BP. Surgical therapy rates of patients with BRONJ stages 1, 2, and 3 were 14.0, 37.6, and 53.5%, respectively. Outcome assessment for 936 patients with BRONJ stage 2 who underwent surgical therapy indicated remission in 46.3% of cases, improvement in 30.6%, disease progression in 5.4%, and no change in 6.1%. Good prognosis (remission or improvement) was seen in 76.9% of cases and poor prognosis (disease progression or no change) was seen in 11.5%. Analysis showed that risk factors for onset of BRONJ (P = .031), surgical procedure (P < .024), condition of the wound (P = .017), and discontinuation of BP (P < .001) were factors affecting prognosis. CONCLUSION: The number of patients with BRONJ has increased in Japan. Attention to oral BP and proper treatment is required to minimize the number of cases. Surgical therapy seems to be effective for BRONJ stage 2.
Authors: Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura Journal: Bone Date: 2019-03-26 Impact factor: 4.398
Authors: M Kamimura; A Taguchi; M Komatsu; H Koiwai; R Ashizawa; A Ichinose; K Takahara; S Uchiyama; H Kato Journal: Osteoporos Int Date: 2018-11-20 Impact factor: 4.507
Authors: Guilherme Simpione; Rogério J Caldas; Mariana Q S Soares; Izabel R F Rubira-Bullen; Paulo S S Santos Journal: J Clin Exp Dent Date: 2020-03-01